CHAIRMAN'S MESSAGE
 
 

ABOUT US

Uni-Bio Science Group always keeps its own vision and mission based on adjusted real value.

2017

  • Uni-Bio Science annual sales hits CNY 100,000,000
  • Launch of Mitiglinide, oral anti-diabetic drug under the registered brand name 博康泰(Bokangtai)
  • HeungKong Great Health Fund I injects HKD$120 million into Uni-Bio Science and becomes its strategic shareholder

2015

  • Uni-Bio Science acquires exclusive global rights to Type 2 diabetes drug Mitiglinide from Jiangsu Hansoh Pharmaceuticals
  • Uni-Bio Science receives newest cGMP certification for its manufacturing line in Beijing.
  • Uni-Bio Science announces positive phase III results for Uni-E4 in Type 2 diabetes.
  • Uni-PTH acceted for CFDA review.

2014

  • Completed Phase III clinical trials for Uni-PTH in menopausal osteoporsis.

2013

  • Uni-Bio receives newest cGMP certification for its manufacturing line in Shenzhen.

2008

  • Received national grants for Uni-E4 and Uni-EPO-Fc as key innovative project.

2007

  • Shenzhen Watsin becomes a wholly owned subsidiary of Uni-Bio Science Group.
  • Received provincial grant from Guangzhou province in recognition of Uni-PTH, Uni-E4 and Uni-EPO-Fc as key innovative projects.

2006

  • Beijing Genetech becomes wholly owned subsidiary of Uni-Bio Science Group

2001

  • Uni-Bio Science Group lists on the Hong Kong Stock Exchange

Corporate Awards

2015 Hong Kong Business High Flyer Awards Healthcare solutions

This award recognises 
the company’s efforts in innovation, demonstrating its commitment to excellence in both operations and customer focus

2015 Hong Kong Business Listed Companies Awards

This award recognises 
the company’s focus in innovation within its industry

2015 Hong Kong Investor Relations Association Winner Best IR small cap

This award recognises 
the company’s focus on good investor relations practices and corporate governance